Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could significantly improve the effectiveness of peptide-based cancer vaccines, according to a new study published in Advanced Functional Materials. The breakthrough centers on a new class of materials called lipopeptide hydrogels (LPHs), which show promise in boosting immune responses and possess adjuvant-like properties.

West Virginia University microbiologists have identified an antibody that can kill one of the most drug-resistant bacteria. Now, supported by a $3.5 million grant from the National Institute of Allergy and Infectious Diseases, they want to determine whether it can be combined with other antibiotics to produce a potent treatment against infection.

A new study published in Nature Communications shows that oral fecal microbiota transplantation (FMT) is a feasible and safe addition to preventing graft-versus-host disease in patients undergoing stem cell transplantation for blood cancers.

A new class of lipids developed by Penn Engineers improve the rates at which lipid nanoparticles (LNPs) successfully deliver RNA therapeutics and gene editing tools, promising to increase their effectiveness of such treatments.

A person’s lifetime risk for cancer may begin before they are even born, reports a paradigm-shifting study by Van Andel Institute scientists. The findings, published in Nature Cancer, identified two distinct epigenetic states that arise during development and are linked to cancer risk. One of these states is associated with a lower lifetime risk while the other is associated with a higher lifetime risk.